Depression, behavior changes may start in Alzheimer’s even before memory changes – Depression and other behavior changes may show up in people who will later develop Alzheimer’s disease even before they start having memory problems, reported by researchers in the medical journal of the American Academy of Neurology.
Cleveland Clinic identifies mechanism in Alzheimer’s-related memory loss — Study uncovers role of Neuroligin-1 protein – Cleveland Clinic researchers have identified a protein in the brain that plays a critical role in the memory loss seen in Alzheimer’s patients. The protein – Neuroligin-1 (NLGN1) – is known to be involved in memory formation; this is the first time it’s been linked to amyloid-associated memory loss.
High good and low bad cholesterol levels are healthy for the brain, too – High levels of “good” cholesterol and low levels of “bad” cholesterol are correlated with lower levels of the amyloid plaque deposition in the brain that is a hallmark of Alzheimer’s disease, UC Davis researchers have found.
Vitamin E May Delay Decline in Mild-to-Moderate Alzheimer’s Disease — Study Shows Benefit in Activities of Daily Living and Savings in Caregiver Time with Vitamin E – A new research suggests that alpha tocepherol, fat-soluble Vitamin E and antioxidant, may slow functional decline (problems with daily activities such as shopping, preparing meals, planning, and traveling) in patients with mild-to-moderate Alzheimer’s disease and decrease caregiver burden.
Are concussions related to Alzheimer’s disease? – A history of concussion involving at least a momentary loss of consciousness may be related to the buildup of Alzheimer’s-associated plaques in the brain, revealed by researchers in Neurology, the medical journal of the American Academy of Neurology.
Copper identified as culprit in Alzheimer’s disease – Copper appears to be one of the main environmental factors that trigger the onset and enhance the progression of Alzheimer’s disease by preventing the clearance and accelerating the accumulation of toxic proteins in the brain.
Rush scientists identify buphenyl as a possible drug for Alzheimer’s disease – Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer’s disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood.
Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer’s Disease – Although several pharmaceutical companies in US have experienced setbacks with Alzheimer’s compounds, Merck & Co., Inc. hopes to defy the odds with plans to take a Alzheimer pill into a Phase II/III clinical study with patients who suffer from mild-to-moderate stages of the Alzheimer’s disease.
Binge drinking increases the risk of cognitive decline in older adults – Researchers from the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, suggesting a link between binge drinking in older adults and the risk of developing dementia. The work is supported by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care in the South West Peninsula (NIHR PenCLAHRC).